1Sorsby, A. Rep. public health med. subj. no. 128. London: HMSO, 1972. (Cited by Ghafour IM et al., 1983.)
2Ghafour, JM, Allan, D, Foulds, WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983; 67: 209–13.
3Leibowitz, HM, Krueger, DE, Maunder, LR et al. The Framingham eye study monograph: an opthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration and visual acuity in a general population of 2631 adults. Surv Ophthalmol 1980; 24 (suppl): 335–610.
4Wormald, RPL, Wright, LA, Courtney, P, Beaumont, B, Haines, AP. Visual problems in the elderly population and implications for services. BMJ 1992; 304: 1226–29.
5Trevor-Roper, P. The world through blunted sight. London: Penguin, 1988.
6Jay, J, Devlin, M. The increasing frequency of surgery for cataract. Eye 1990; 4: 127–32.
7Courtney, P. The national cataract surgery survey: 1. Method and descriptive features. Eye 1992; 6: 487–92.
8Jay, JL, Chakraborti, HS, Morrison, JD. Quality of vision through diffractive bifocal intraocular lenses. Br J Ophthalmol 1991; 75: 359–66.
9Cheng, H. Causes of cataract. Age, sugars and probably ultraviolet B-radiation. BMJ 1989; 298: 1470–71.
10Klein, R, Klein, BEK, Jensen, MS et al. The relation of socioeconomic factors to age-related cataract, maculopathy and impaired vision. The Beaver dam eye study. Ophthalmol 1994; 101: 1969–79.
11West, DK, Rosenthal, FS, Bressler, SB et al. Exposure to sunlight and other risk factors for age related macular degeneration. Arch Ophthalmol 1989; 107: 875–79.
12Taylor, HR. Long-term effects of visible light on the eye. Arch Ophthalmol 1992; 110: 99–104.
13Seddon, JM, Christen, WG, Manson, JE, Buring, JE, Sperduto, RD, Hennekens, CH. Low-dose aspirin and risks of cataract in a randomised trial of US physicians. Arch Ophthalmol 1991; 109: 252–55.
14Berry, DD, van Buskirk, EM, Shields, MB. Betaxolol and timolol. A comparison of efficacy and side effects. Arch Ophthalmol 1984; 102: 42–45.
15Hitchings, RA. Perimetry – back to the future? [Editorial]. Br J Ophthalmol 1994; 78: 805–806.
16Macular Photocoagulation Study Group. Argon laser photocoagaulation for neovascular maculopathy. Five year results from randomised clinical trials. Arch Ophthalmol 1991; 109: 1109–14.
17Yannuzzi, LA, Slakter, JS, Sorenson, JA, Guyer, DR, Orlock, DA. Digital indocyanine green videoangiography and choroidal neovascularisation. Retina 1992; 12: 191–213.
18Grizzard, WS, Beck, RW. Twin study of age related macular degeneration. Invest Ophthalmol Vis Sci 1994; 35: 4–.
19Seddon, J, Ajani, U, Sperduto, R et al. Dietary fat intake and age related macular degeneration. Invest Ophthalmol Vis Sci 1994; 35: 2003–.
20Vingerling, JR, Dielemans, I, Bots, ML et al. Atherosclerosis is associated with late age related maculopathy. Invest Ophthamol Vais Sci 1994; 35: 2003–.
21Lee, Y, Lanar, M, Jacques, P, Taylor, A. The relatoinship between long term Vitamin C intake and the presence of macular drusen. Invest Ophthalmol Vis Sci 1994; 35: 2004–.
22Klein, R, Klein, BEK, Moss, SE, Davis, MD, De Mets, DL. The Wisconsin epidemiological study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527–32.
23Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Am J Ophthalmol 1978; 85: 82–106.
24Early Treatment Diabetic Retinopathy Study Research Group. ETDRS Report No. 2. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Ophthalmology 1987; 94: 761–74.
25Krans, HMJ, Porta, M, Keen, H. Diabetes care and research in Europe: the St. Vincent Declaration action programme. Copenhagen: WHO, 1992.
26Kritzinger, EE. Management of diabetic maculopathy. Semin Ophthalmol 1986; 1: 171–78.
27Aaberg, TM, Abrahams, GW. Changing indications and techniques for vitrectomy in management of complications of diabetic retinopathy. Ophthalmology 1987; 94: 775–79.
28Diabetic Retinopathy Vitrectomy Study Research Group. Report no. 5. Early vitrectomy for severe vitreous haemorrhage in diabetic retinopathy. Four-year results of a randomised trial. Arch Ophthalmol 1990; 108: 958–64.
29Kohner, EM. The effect of diabetic control on diabetic retinopathy. Eye 1993; 7: 309–11.
30The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977–86.
31Goldberg, MF, Jampol, L. Knowledge of diabetic retinopathy before and 18 years after the Airlie House Symposium on treatment of diabetic retinopathy. Ophthalmology 1987; 94: 741–46.
32Lightman, S. Does aldose reductase have a role in the development of the ocular complications in diabetes? Eye 1993; 7: 238–41.
33Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report no. 8. Opthalmology 1991; 98: 757–65.
34Brahams, D. Medicine and the law: eye monitoring in diabetes. Lancet 1992; 339: 863–64.
35MacCuish, AC. Early detection and screening for diabetic retinopathy. Eye 1993; 7: 254–59.
36Kritzinger, EE. Blind ignorance [Editorial]. Pract Diabetes 1990; 7: 100.
37Keenan, JM, Kritzinger, EE, Dodson, PM. Management of retinal vein occlusion. Br J Hosp Med 1993; 49: 268–73.
38Dodson, PM, Kritzinger, EE. Management of retinal vein occlusion. BMJ 1987; 295: 1434–35.
39Dodson, PM, Galton, DJ, Hamilton, AM, Blach, RK. Retinal vein occlusion and the prevalence of lipoprolein abnormalities. Br J Ophthalmol 1982; 66: 161–64.
40Dodson, PM, Kubicki, AJ, Taylor, KG, Kritzinger, EE. Medical conditions underlying recurrence of retinal vein occlusion. Br J Ophthalmol 1985; 69: 493–96.
41Dodson, PM, Westwick, J, Marks, G, Kakkar, VV, Galton, DJ. B-thromboglobulin and platelet factor 4 levels in retinal vein occlusion. Br J Ophthalmol 1983; 67: 143–46.
42Dodson, PM, Kritzinger, EE. Underlying medical conditions in young patients and ethnic differences in retinal vein occlusion. Trans Ophthalmol Soc U K 1985; 104: 114–19.
43Margalal, LE, Brown, GC, Angsberger, JJ et al. Efficacy of panretinal photocoagulation in preventing neovascular glaucoma following ischemic central 26 retinal vein obstruction. Ophthalmology 1982; 89: 780–84.
44Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1985; 99: 218–19.
45Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularisation and vitreous haemorrhage in branch vein occlusion: a randomised trial. Arch Ophthalmol 1986; 104: 34–41.
46Miyamoto, H, Ogura, Y, Honda, Y. Long term results of hyperbaric oxygen therapy for macular edema after retinal vein occlusion. Invest Ophthalmol Vis Sci 1993; 34: 841.
47Skidmore, EC, Spoor, TC, McHenry, JG. Optic nerve decompression for central retinal vein occlusion. Invest Ophthalmol Vis Sci 1994; 35: 2086–.
48Morrell, AJ, Thompson, DA, Gibson, JM, Kritzinger, EE, Drasdo, N. Electroretinography as a prognostic indicator of neovascularisation in CRVO. Eye 1991; 5: 362–68.
49Sandor, EV, Millman, A, Croxon, TS, Mildvan, D. Herpes zoster ophthalmicus in patients at risk for AIDS. Am J Ophthalmol 1986; 101: 153–55.
50Marsh, RJ, Cooper, M. Ophthalmic herpes zoster. Eye 1993; 7: 350–70.